Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Revenue (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Revenue data on record, last reported at -$19.3 million in Q4 2025.

  • For Q4 2025, Revenue fell 110.6% year-over-year to -$19.3 million; the TTM value through Dec 2025 reached $324.7 million, down 48.58%, while the annual FY2025 figure was -$82.3 million, 113.04% down from the prior year.
  • Revenue reached -$19.3 million in Q4 2025 per COLL's latest filing, up from -$21.8 million in the prior quarter.
  • Across five years, Revenue topped out at $188.0 million in Q2 2025 and bottomed at -$21.8 million in Q3 2025.
  • Average Revenue over 5 years is $113.2 million, with a median of $132.6 million recorded in 2022.
  • Peak YoY movement for Revenue: skyrocketed 373.72% in 2022, then plummeted 113.66% in 2025.
  • A 5-year view of Revenue shows it stood at $27.4 million in 2021, then surged by 373.72% to $129.6 million in 2022, then grew by 15.53% to $149.7 million in 2023, then increased by 21.51% to $181.9 million in 2024, then tumbled by 110.6% to -$19.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were -$19.3 million in Q4 2025, -$21.8 million in Q3 2025, and $188.0 million in Q2 2025.